Literature DB >> 30590836

The lomustine crisis: awareness and impact of the 1500% price hike.

Jennie W Taylor1, Terri Armstrong2, Albert H Kim3, Monica Venere4, Alvina Acquaye2, Deborah Schrag1, Patrick Y Wen5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30590836      PMCID： PMC6303421          DOI： 10.1093/neuonc/noy189

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  9 in total

1.  Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.

Authors:  Roger J Packer; Amar Gajjar; Gilbert Vezina; Lucy Rorke-Adams; Peter C Burger; Patricia L Robertson; Lisa Bayer; Deborah LaFond; Bernadine R Donahue; MaryAnne H Marymont; Karin Muraszko; James Langston; Richard Sposto
Journal:  J Clin Oncol       Date:  2006-09-01       Impact factor: 44.544

2.  Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.

Authors:  Jan C Buckner; Edward G Shaw; Stephanie L Pugh; Arnab Chakravarti; Mark R Gilbert; Geoffrey R Barger; Stephen Coons; Peter Ricci; Dennis Bullard; Paul D Brown; Keith Stelzer; David Brachman; John H Suh; Christopher J Schultz; Jean-Paul Bahary; Barbara J Fisher; Harold Kim; Albert D Murtha; Erica H Bell; Minhee Won; Minesh P Mehta; Walter J Curran
Journal:  N Engl J Med       Date:  2016-04-07       Impact factor: 91.245

3.  Off-patent drugs at brand-name prices: a puzzle for policymakers.

Authors:  Naren P Tallapragada
Journal:  J Law Biosci       Date:  2016-02-25

4.  Lomustine and Bevacizumab in Progressive Glioblastoma.

Authors:  Wolfgang Wick; Thierry Gorlia; Martin Bendszus; Martin Taphoorn; Felix Sahm; Inga Harting; Alba A Brandes; Walter Taal; Julien Domont; Ahmed Idbaih; Mario Campone; Paul M Clement; Roger Stupp; Michel Fabbro; Emilie Le Rhun; Francois Dubois; Michael Weller; Andreas von Deimling; Vassilis Golfinopoulos; Jacoline C Bromberg; Michael Platten; Martin Klein; Martin J van den Bent
Journal:  N Engl J Med       Date:  2017-11-16       Impact factor: 91.245

5.  CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014.

Authors:  Quinn T Ostrom; Haley Gittleman; Peter Liao; Toni Vecchione-Koval; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2017-11-06       Impact factor: 12.300

6.  Three Steps Toward a More Sustainable Path for Targeted Cancer Drugs.

Authors:  Justin E Bekelman; Steven Joffe
Journal:  JAMA       Date:  2018-06-05       Impact factor: 56.272

7.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

8.  Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

Authors:  Martin J van den Bent; Alba A Brandes; Martin J B Taphoorn; Johan M Kros; Mathilde C M Kouwenhoven; Jean-Yves Delattre; Hans J J A Bernsen; Marc Frenay; Cees C Tijssen; Wolfgang Grisold; László Sipos; Roelien H Enting; Pim J French; Winand N M Dinjens; Charles J Vecht; Anouk Allgeier; Denis Lacombe; Thierry Gorlia; Khê Hoang-Xuan
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

9.  Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics.

Authors:  Kathleen A Cronin; Andrew J Lake; Susan Scott; Recinda L Sherman; Anne-Michelle Noone; Nadia Howlader; S Jane Henley; Robert N Anderson; Albert U Firth; Jiemin Ma; Betsy A Kohler; Ahmedin Jemal
Journal:  Cancer       Date:  2018-05-22       Impact factor: 6.860
  9 in total
  4 in total

1.  Short-term outcomes associated with temozolomide or PCV chemotherapy for 1p/19q-codeleted WHO grade 3 oligodendrogliomas: A national evaluation.

Authors:  Nayan Lamba; Malia McAvoy; Vasileios K Kavouridis; Timothy R Smith; Mehdi Touat; David A Reardon; J Bryan Iorgulescu
Journal:  Neurooncol Pract       Date:  2022-01-14

Review 2.  An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5.

Authors:  Tamara Lah Turnšek; Xuanmao Jiao; Metka Novak; Sriharsha Jammula; Gina Cicero; Anthony W Ashton; David Joyce; Richard G Pestell
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

3.  Improving the Clinical Treatment of Vulnerable Populations in Radiation Oncology.

Authors:  Shearwood McClelland; Daniel G Petereit; Ross Zeitlin; Cristiane Takita; Gita Suneja; Robert C Miller; Curtiland Deville; Malika L Siker
Journal:  Adv Radiat Oncol       Date:  2020-08-06

Review 4.  Continuous Flow Synthesis of Anticancer Drugs.

Authors:  Mara Di Filippo; Marcus Baumann
Journal:  Molecules       Date:  2021-11-19       Impact factor: 4.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.